Zacks Investment Research on MSN
NVO vs. VKTX: Which obesity stock could deliver bigger gains?
Novo Nordisk NVO and Viking Therapeutics VKTX both operate in the obesity-treatment market. Novo Nordisk is recognized as a leader in the GLP-1 treatment space, marketing its semaglutide drugs under ...
12hon MSN
GLP-1s are dramatically shifting people’s sex drives. Scientists are finally figuring out why.
The research on the ups and downs of new weight loss drugs.
Regeneron Pharmaceuticals, Inc. Q3 earnings preview: click for how Dupixent growth, positive Phase 3 results, and a ...
Novo Nordisk enters the final stretch of 2026 with a regulatory and clinical calendar that is unusually crowded — and ...
Nordea reiterates its buy rating on pharmaceutical company Novo Nordisk, with a price target of 380 Danish kroner. The bank sees several positive price catalysts in the short term, including the ...
Novo Nordisk bestätigt die geleakten Registerdaten nicht; J.P. Morgan rechnet bei den Quartalszahlen mit einer höheren ...
Ein auf Social Media geteiltes Video, in dem Schauspielerin Son Ye-jin Käse-Sticks isst, sowie ihre Kleidung im Urlaub haben ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results